Health & Life SciencesGS2 · GS319 September 2026

Counterfeit Cancer and Antibiotic Injections Traced From a Bengaluru Farmhouse to Wholesaler Krupa Healthcare

Open in the app — quiz, notes, Mistake Vault

The news

In mid-August an agricultural labourer in C.K. Tandya village in South Bengaluru district, formerly Ramanagara, along the Bengaluru-Mysuru expressway, noticed a heap of medical waste on a strip of farmland and reported it to the beat police at Taverekere police station. Villagers had already been whispering about men entering the eight-acre walled farmhouse on a scooter without a number plate and about courier and e-commerce vehicles making regular trips to the secluded property, which the police say had been rented about a year earlier. After surveillance, the police and Karnataka's health department entered the premises, found labels, medicine boxes and packaging material, and joined officers of the State Drugs Control Department for a raid on August 18. Four people were taken into custody. Investigators say low-cost, substandard or expired formulations procured from other States were transferred into fresh vials and given counterfeit labels so that they would appear to be genuine products of established pharmaceutical companies. The seizure included more than 5,600 vials of counterfeit antibiotic injections and was valued at ₹4.91 crore; ledgers, invoices and mobile phones gave the police the supply chain. A Special Investigation Team traced the trail to Krupa Healthcare, a wholesale pharmaceutical distributor in Bengaluru, whose owner Veeresh Kumar Jain was arrested; the police say he employed more than 15 medical representatives and paid commissions to push stock offered to hospitals at discounts of up to 50%. The counterfeits included critical-care injections and cancer medicines. Simultaneous searches followed across Karnataka, Himachal Pradesh, Haryana, Tamil Nadu, Maharashtra and Telangana, and the police are hunting Bengaluru resident R. Prashant, said to be Jain's partner and currently in Azerbaijan. The suspect medicines have reached more than 90 hospitals and clinics. Karnataka has published the list of antibiotics seized in the Bidadi raid but not the oncology drugs, the batch numbers or the hospitals; Health Minister U.T. Khader told The Hindu the full list had gone to the Union government and all States but that disclosure was for the SIT to make.

The chain in one line: Cancer drugs priced beyond reach → a discount market grows around desperate buyers → expired stock is revialled at a rented farmhouse → a wholesaler with medical representatives pushes it at 50% off → it enters 90-plus hospitals → a labourer reports dumped waste and the chain becomes visible

Static syllabus linkage

Section 17B is the definition the whole case turns on. The Drugs and Cosmetics Act, 1940 distinguishes three defects. Section 17 defines a misbranded drug, Section 17A an adulterated drug, and Section 17B a spurious drug — one that imitates or is a substitute for another, or is labelled or presented in a manner likely to deceive, or purports to be the product of a manufacturer of whom it is not truly a product. Section 18 prohibits the manufacture, sale, stocking, distribution and exhibition for sale of such drugs. A drug that merely fails a quality test is 'not of standard quality' under Section 16; a drug wearing another company's identity is spurious, and the punishment is far heavier.
Regulation is split between the Centre and the States by design. The Central Drugs Standard Control Organisation, headed by the Drugs Controller General of India under the Directorate General of Health Services in the Ministry of Health and Family Welfare, approves new drugs, clinical trials and imports and lays down standards. Licensing of manufacture, sale and distribution, and the inspectorate that enforces it, sit largely with State Drugs Control Departments. This is why a network operating across six States is investigated by one State's Special Investigation Team, and why the Karnataka minister's remedy was to circulate a list to other States rather than to act in them.
Two statutory bodies advise, and candidates confuse them. Section 5 of the Act creates the Drugs Technical Advisory Board, which advises the Central and State governments on technical matters arising out of the administration of the Act. Section 7 creates the Drugs Consultative Committee, whose function is to advise on securing uniformity across India in the administration of the Act. The first is technical, the second is about harmonising how the States apply the law — a distinction that matters precisely in a case like this one.
The Mashelkar Committee said this in 2003 and the diagnosis has not changed. The expert committee chaired by R.A. Mashelkar, constituted to examine drug regulatory issues including the problem of spurious drugs, recommended a strengthened and better-staffed central regulator, uniform enforcement across States and deterrent punishment. The Act was subsequently amended in 2008 to make the manufacture or sale of spurious drugs likely to cause death or grievous hurt punishable with imprisonment of not less than ten years extending to life, and to allow States to set up special courts. The shortfall since has been in inspectorate capacity and prosecution, not in the text of the statute.

Why UPSC loves this

This sits squarely in the GS2 health governance box. The syllabus asks about 'issues relating to development and management of social sector/services relating to health' and about 'statutory, regulatory and various quasi-judicial bodies'. A spurious-drug network is the cleanest available illustration of a regulatory body whose powers are adequate on paper and whose field presence is not.
Regulatory capacity is a recurring Mains theme, not a one-off. The paper has repeatedly asked why Indian regulators under-deliver — on food safety, on pharmaceuticals, on medical education. The productive answer is always the same three-part one: fragmented jurisdiction, understaffed inspectorates, and penalties that are severe in statute but rarely imposed. This story supplies fresh, dated evidence for all three.
Ethics papers like the informed-consent angle. Patients treated with suspect stock have not been told. The duty to disclose a risk already incurred, when disclosure will cause distress and cannot undo the harm, is a standard GS4 dilemma and here it comes with named institutions and a live investigation.

Prelims nuggets

The Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945 are the parent legislation for the manufacture, sale, distribution and import of drugs and cosmetics in India.
Section 17B of the Act defines a spurious drug; Section 17 defines a misbranded drug; Section 17A defines an adulterated drug; Section 18 prohibits their manufacture, sale, stocking and distribution.
Section 5 of the Act constitutes the Drugs Technical Advisory Board to advise on technical matters; Section 7 constitutes the Drugs Consultative Committee to advise on uniformity of administration across India.
The Central Drugs Standard Control Organisation functions under the Directorate General of Health Services in the Ministry of Health and Family Welfare, and is headed by the Drugs Controller General of India.
Licensing and enforcement for manufacture, sale and distribution of drugs rest largely with State Drugs Control Departments, while approval of new drugs, clinical trials and imports is a central function.
The All India Drug Action Network is a network of non-profit organisations working to increase access to and improve the rational use of essential medicines; the Drug Action Forum, Karnataka is one of its constituents.
Following the 2008 amendment, manufacture or sale of spurious or adulterated drugs likely to cause death or grievous hurt is punishable with imprisonment of not less than ten years extending to imprisonment for life, and States may constitute special courts for trial of such offences.

Analysis

The detection came from a villager, which is the finding, not the colour. A network with a rented farmhouse, more than fifteen medical representatives, inter-State procurement and distribution into ninety-odd hospitals ran for about a year and was surfaced by a labourer reporting dumped waste. No inspection, no sampling programme and no hospital procurement check caught it. The uncomfortable inference is that the counterfeits were not detected by the system at any point in the chain — which means the seizure number tells us what one raid recovered, not what the network moved.
A 50% discount on an oncology injection should itself be a red flag to the buyer. The police say stock was offered to hospitals at discounts of up to 50%, with commissions to medical representatives. Hospitals are sophisticated purchasers; a discount of that size on a patented critical-care product has no legitimate commercial explanation. The honest reading is that the counterfeiters exploited a procurement culture in which price is negotiated aggressively and provenance is not verified. That is a shared failure, and the lawyer S.V. Joga Rao's formulation — that the duties of hospitals and regulators operate concurrently though they differ in nature — is the right frame for an answer.
Non-disclosure protects the investigation and abandons the patient. Karnataka has released the antibiotic list but not the oncology drugs, the batch numbers or the hospitals. There is a real investigative reason: premature disclosure can let the accused destroy records and can trigger panic among patients mid-treatment. There is also a real countervailing duty, because a patient who does not know cannot ask her oncologist to re-examine a non-response. The defensible middle course is to give batch numbers and hospital names to treating institutions under confidence immediately, and to publish once the SIT files its report — what cannot be defended is telling neither the public nor the clinicians.
The price of cancer medicine is the demand side of counterfeiting. A single vial at ₹1,65,990, a course costing about ₹20 lakh, buy-one-get-one offers routed through referrals — Dr. Gopal Dabade's point that better access to good-quality affordable treatment is the crux is an economic claim, not a slogan. Where the legitimate price is far above what patients can pay, a parallel market forms, and enforcement alone cannot close a gap created by price. Patent-term expiry, compulsory licensing where warranted, and inclusion of high-cost oncology drugs in price control are therefore anti-counterfeiting measures as much as access measures.
The harm from a fake cancer drug is uniquely hard to see. Dr. Nitish Ranjan Acharya's observation deserves to be the centre of an answer: when a counterfeit oncology drug fails, the failure looks like disease progression or acquired resistance. The clinical signal that would normally expose a bad batch is absent, which means the usual pharmacovigilance feedback loop does not operate for exactly the class of drug where the stakes are highest. Detection here has to be upstream — at procurement and supply-chain verification — because it will not happen at the bedside.
The counter-view is that naming hospitals now would destroy more than it saves. It is worth stating the case against disclosure honestly. Publishing a list of ninety hospitals before the SIT has established which received counterfeit stock would brand institutions that bought in good faith, may collapse public confidence in private oncology care generally, and could lead patients to abandon treatment that is in fact working. The answer is not that transparency is costless; it is that the cost of concealment falls on individual patients who have no alternative source of information, while the cost of disclosure falls on institutions that can defend themselves.

Possible Mains question

"A regulatory statute is only as strong as the inspectorate that enforces it." In the light of recent cases of spurious and substandard drugs entering the treatment chain, examine the structural weaknesses in India's drug regulatory architecture and suggest reforms. (15 marks, 250 words)

Model approach

Introduction. Open with the statutory architecture in two sentences — the Drugs and Cosmetics Act, 1940, the Section 17B definition of a spurious drug, and the split under which the Centre approves while the States license and enforce. Do not open with the Bengaluru case; use it as evidence later, which is where an example belongs.
Body — locate the weaknesses structurally, not anecdotally. Four heads carry the answer: fragmented jurisdiction, so that an inter-State network faces one State's investigators; an under-resourced inspectorate, which is the point made by the Drug Action Forum that drug inspectors are the first line of foot soldiers but are not adequately equipped; weak prosecution despite severe statutory punishment after the 2008 amendment; and an absence of supply-chain traceability, so that authenticity cannot be verified at the point of dispensing.
Body — bring in the demand side. Argue that enforcement alone cannot close a market created by price. Use the cost of oncology therapy and the 50% discount offer to show that the counterfeit market exists because the legitimate one is unaffordable, and connect this to price control, generic substitution and the National List of Essential Medicines.
Body — the accountability and disclosure question. One short paragraph on what happens after detection: the duty of hospitals to trace and inform, the duty of regulators to publish batch numbers, and the tension with an ongoing investigation. This is where most answers stop at 'strict action should be taken' and lose the marks.
Conclusion. Recommend concretely and briefly — track-and-trace barcoding extended down to the retail pack, risk-based inspection using licensing and sampling data, a common national database of licences and prosecutions so that a person barred in one State cannot operate in another, and filling of drug inspector vacancies against the sanctioned norm. Close on the principle that a patient cannot verify a medicine and must therefore be able to rely on the State that licensed it.

Administrator's brainstorm

You are the Deputy Commissioner of a district where three hospitals appear on the confidential list of institutions that received suspect stock. The SIT has asked you not to disclose. A local newspaper has the list and is publishing tomorrow. What do you do tonight?

Accept that secrecy has already failed and spend the night preparing for disclosure rather than trying to prevent it. Inform the SIT immediately that the list is out, so that any evidence-preservation steps they need are taken before dawn. Convene the three hospital administrators and the Chief Medical Officer at once and require each hospital to reconcile its purchase records against the batch numbers overnight and to identify patients who received those batches. Have a helpline and a named nodal officer ready by morning, and a factual statement that says what is known, what is not yet known and what a worried patient should do. The public will forgive an administration that was overtaken by events; it will not forgive one that was silent for another week after the story broke.

A private oncology hospital in your district tells you it bought the stock in good faith from a licensed wholesaler, has valid invoices, and will be ruined if named. It asks you to keep it out of the public statement. How do you respond?

Tell it plainly that the decision on naming is not yours to trade and that any assurance to the contrary would be worthless. Then be genuinely useful within the law: record its invoices and licence verification on the file, because good-faith purchase from a licensed dealer is material both to prosecution under the Act and to its own defence, and say so in the district's statement in general terms — that the institutions concerned purchased from a licensed distributor and are cooperating. Require it in return to write to every affected patient within seventy-two hours and to bear the cost of re-testing or re-treatment where clinically indicated. Reputation is protected by demonstrated conduct after the event, not by an administrator's silence.

You are the State Drugs Controller. Your inspectorate has a third of its sanctioned posts vacant and you are asked to guarantee that no counterfeit drug reaches a hospital in your State. What do you say, and what do you actually do?

Do not give a guarantee you cannot keep; say instead that you will make the probability of detection high enough to change the economics for the counterfeiter. Move from routine sampling to risk-based inspection — prioritise wholesalers whose purchase invoices show high-value oncology and critical-care products without a corresponding manufacturer authorisation, because that anomaly is already visible in returns you hold. Ask the government for the vacancies to be filled and put the request on record with the number of licensed premises per inspector, so that the capacity gap is documented rather than absorbed silently. And publish a quarterly report of samples drawn, failures found and prosecutions launched; a regulator that publishes its own shortfall is harder to ignore than one that reassures.